Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The primary objective of this trial is to demonstrate the equivalence, in terms of immunogenicity, of three different industrial lots of the investigational vaccine thereby supporting consistency of the manufacturing process.

Secondary Objectives:

Immunogenicity

To demonstrate that the investigational vaccine induces an immune response at least as good as the one induced by the reference vaccine, in terms of antibody titers.

To assess the immunogenicity of the investigational vaccine using parameters defined in the European Medicines Agency (EMEA) Note for Guidance (CPMP/BWP/214/96).

Safety:

To demonstrate that the investigational vaccine is at least as well tolerated as the reference vaccine, in terms of defined safety profile.

To describe the safety profile after vaccination.

Comfort of the vaccination assessment:

To assess the pain immediately after the injection using a Verbal Rating Scale. To describe the vaccination comfort after the injection using a -Patient-Reported Outcome questionnaire: the Vaccination Comfort Questionnaire.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: Inactivated Split-virion influenza vaccine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Biological: Inactivated Split-virion influenza vaccine | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Biological: Inactivated Split-virion influenza vaccine | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Biological: Inactivated Split-virion influenza vaccine | Intervention Type: BIOLOGICAL; Name: Inactivated Split-virion influenza vaccine; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Inactivated Split-virion influenza vaccine; Assigned to Arm(s): 2 | Intervention Type: BIOLOGICAL; Name: Inactivated Split-virion influenza vaccine; Assigned to Arm(s): 3 | Intervention Type: BIOLOGICAL; Name: Inactivated Split-virion influenza vaccine; Assigned to Arm(s): 4
B: Arm Label: GSK1562902A non-AD F1 Primed Group; Type: EXPERIMENTAL; Interventions: Biological: Pandemic influenza candidate vaccine (GSK1562902A) - 2 doses | Arm Label: GSK1562902A non-AD F2 Primed Group; Type: EXPERIMENTAL; Interventions: Biological: Pandemic influenza candidate vaccine (GSK1562902A) - 2 doses | Arm Label: GSK1562902A non-AD F3 Primed Group; Type: EXPERIMENTAL; Interventions: Biological: Pandemic influenza candidate vaccine (GSK1562902A) - 2 doses | Arm Label: GSK1562902A non-AD F4 Primed Group; Type: EXPERIMENTAL; Interventions: Biological: Pandemic influenza candidate vaccine (GSK1562902A) - 2 doses | Arm Label: GSK1562902A AD F1 Primed Group; Type: EXPERIMENTAL; Interventions: Biological: Pandemic influenza candidate vaccine (GSK1562902A) - 1 dose | Arm Label: GSK1562902A AD F2 Primed Group; Type: EXPERIMENTAL; Interventions: Biological: Pandemic influenza candidate vaccine (GSK1562902A) - 1 dose | Arm Label: GSK1562902A AD F3 Primed Group; Type: EXPERIMENTAL; Interventions: Biological: Pandemic influenza candidate vaccine (GSK1562902A) - 1 dose | Arm Label: GSK1562902A AD Approved F4 Primed Group; Type: EXPERIMENTAL; Interventions: Biological: Pandemic influenza candidate vaccine (GSK1562902A) - 1 dose | Arm Label: Control Group; Type: EXPERIMENTAL; Interventions: Biological: Pandemic influenza candidate vaccine (GSK1562902A) - 2 doses | Intervention Type: BIOLOGICAL; Name: Pandemic influenza candidate vaccine (GSK1562902A) - 1 dose; Assigned to Arm(s): GSK1562902A AD Approved F4 Primed Group, GSK1562902A AD F1 Primed Group, GSK1562902A AD F2 Primed Group, GSK1562902A AD F3 Primed Group | Intervention Type: BIOLOGICAL; Name: Pandemic influenza candidate vaccine (GSK1562902A) - 2 doses; Assigned to Arm(s): Control Group, GSK1562902A non-AD F1 Primed Group, GSK1562902A non-AD F2 Primed Group, GSK1562902A non-AD F3 Primed Group, GSK1562902A non-AD F4 Primed Group
C: Arm Label: TIV + aH5N1; Type: EXPERIMENTAL; Interventions: Biological: Trivalent influenza virus vaccine (TIV), Biological: Adjuvanted monovalent influenza virus vaccine (aH5N1) | Arm Label: PL + aTIV; Type: ACTIVE_COMPARATOR; Interventions: Biological: Placebo (PL), Biological: Adjuvanted trivalent influenza virus vaccine (aTIV) | Intervention Type: BIOLOGICAL; Name: Placebo (PL); Assigned to Arm(s): PL + aTIV | Intervention Type: BIOLOGICAL; Name: Trivalent influenza virus vaccine (TIV); Assigned to Arm(s): TIV + aH5N1 | Intervention Type: BIOLOGICAL; Name: Adjuvanted monovalent influenza virus vaccine (aH5N1); Assigned to Arm(s): TIV + aH5N1 | Intervention Type: BIOLOGICAL; Name: Adjuvanted trivalent influenza virus vaccine (aTIV); Assigned to Arm(s): PL + aTIV
D: Arm Label: FluBlok; Type: EXPERIMENTAL; Interventions: Biological: FluBlok Influenza Vaccination | Arm Label: TIV (Fluzone); Type: ACTIVE_COMPARATOR; Interventions: Biological: TIV (Fluzone) Influenza Vaccination | Intervention Type: BIOLOGICAL; Name: FluBlok Influenza Vaccination; Assigned to Arm(s): FluBlok | Intervention Type: BIOLOGICAL; Name: TIV (Fluzone) Influenza Vaccination; Assigned to Arm(s): TIV (Fluzone)

Answer: A